Scientia Ventures

About The Fund

Scientia Ventures is a venture capital fund specializing in investments within the healthcare and life sciences sectors. They are focused on fueling innovative companies that operate across therapeutics, precision medicine, diagnostics, and various high-impact technology areas including nanotechnology. With an investment thesis centered on intelligent investment in healthcare, they seek to back transformative businesses that advance medical care and patient outcomes. Scientia Ventures believes that 'knowledge is power,' a philosophy that drives their approach to investing in healthcare. The fund has a substantial portfolio, having funded 31 companies and achieving 5 IPOs, indicating a robust track record in identifying and supporting successful ventures. Notable portfolio highlights include Royalty Pharma, known for transforming funding in life sciences with collaborative capital and leading the pharmaceutical royalty business; ADC Therapeutics, which specializes in developing proprietary Antibody Drug Conjugates for treating solid and hematological cancers; and Intra-Cellular Therapies, a biopharmaceutical company founded by Nobel Prize winner Paul Greengard. Scientia Ventures prides itself on contributing more than just capital—they offer strategic insight and support to their portfolio companies throughout their development phases. By employing a knowledgeable and science-driven investment strategy, they have successfully backed companies like Cristcot, Cibus, and FibroGen, all of which have achieved significant milestones in their respective arenas of healthcare and life sciences. Their interest in leveraging artificial intelligence in advancing disease resistance further highlights their commitment to incorporating cutting-edge technologies into the realm of healthcare innovation.